Figure 3. Antitumor effect of different doses of AAV-CBA-hIFN-β.

AAV-CBA-hIFN-β was infused into the striatum of three groups of mice (n = 4) at the following doses: 10¹¹ genome copies (gc), 10¹⁰ gc, 5 × 10⁹ gc. Two weeks later, 5 × 10⁵ U87fluc-mCherry cells were injected at the same coordinates used for vector injection and tumor growth was monitored by bioluminescent imaging. #Only one of four mice in the 5 × 10⁹ gc AAV-CBA-hIFN-β group gave detectable signal at days 12 and 25. AAV-ev, adeno-associated virus–empty vector; CBA, chicken β-actin; EGFRvIII, epidermal growth factor receptor variant III; hIFN-β, human interferon-β; ND, not detected.*P < 0.05.